MedicalResearch.com Interview with:
Héctor Peinado PhD
Microenvironment and Metastasis Laboratory
Molecular Oncology Program
Spanish National Cancer Research Center
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: In this study we detected for the first time BRAF mutation by liquid biopsy in melanoma stage III patients that underwent lymphadenectomy. We obtained a novel biofluid from the drainage implanted 24-48 hours post-lymphadenectomy, called exudative seroma, and profiled BRAF mutation in circulating free DNA and extracellular vesicles.
Those patients positive for BRAF mutation in the seroma had increased risk of relapse, therefore we believe that this technique identifies patients at risk of relapse by identifying residual disease.